Early detection, risk stratification, and drug target identification in pulmonary arterial hypertension with plasma proteomics
Early detection, risk stratification, and drug target identification in pulmonary arterial hypertension with plasma proteomics
Pulmonary arterial hypertension is a rare condition that is clinically heterogenous and often diagnosed late in disease progression. Plasma proteomics offers the potential to diagnose earlier, risk-stratify patients, and identify new drug targets.
Learning Objectives
- Pulmonary arterial hypertension as a clinical condition
- Applying proteomics to risk stratification
- Combining proteomics with genome-wide association studies to identify protein quantitative trait loci associated with the condition
Christopher Rhodes, MA, Cantab, PhD
Senior British Heart Foundation Science Fellow
Senior Lecturer
Imperial College London
Martin R. Wilkins
Professor of Clinical Pharmacology
Vice Dean of Research
Faculty of Medicine
Imperial College London
Early detection, risk stratification, and drug target identification in pulmonary arterial hypertension with plasma proteomics
A presentation by Christopher Rhodes, MA, Cantab, PhD, and Martin R. Wilkins
More webinars
WebinarIdentifying Biomarkers for IBD Diagnosis and Management
In this webinar, you’ll hear how proteomics technology can enhance the identification of biomarkers for the accurate diagnosis of Crohn’s disease and ulcerative colitis, as well as the identification of biomarkers that predict response to TNF inhibitors and other biologics in patients with IBD.
WebinarBoutique Webinar : Predicting Pregnancy Complications with High-Plex Proteomics
The interdisciplinary team, comprising 10-15 scientists and clinician-scientists, is dedicated to advancing diagnostics and therapeutics aimed at enhancing maternal and fetal care. Their primary focus lies in the development of interventions for conditions such as ectopic pregnancy and preeclampsia, alongside the creation of diagnostics to prevent stillbirth.
WebinarYoung blood for old brains and the quest to slow brain aging
Aging leads to the degradation of function in nearly all tissues and organs. This process is marked by significant shifts in gene expression and changes in concentrations of all types of biological molecules. Recent technological progress has allowed biologists to measure an unprecedented number of these molecules throughout an organism